Article information
Full text is only aviable in PDF
REFERENCES
[1]
J Hung, EG Whitford, RW Parsons, DR Hillman.
Association of sleep apnea with myocardial infarction in men.
Lancet, 336 (1990), pp. 261-264
[2]
E Shahar, CW Whitney, S Redline, ET Lee, AB Newman, J Nieto, et al.
Sleep-disordered breathing and cardiovascular disease.
Am J Respir Crit Care Med, 163 (2001), pp. 19-25
[3]
P Peppard, T Young, M Palta, J Skatrud.
Prospective study of the association between sleep-disordered breathing and hypertension.
N Engl J Med, 342 (2000), pp. 1378-1384
[4]
T Young, P Peppard.
Sleep-disordered breathing and cardiovascular disease: epidemiological evidence for a relationship.
Sleep, 23 (2000), pp. 122-126
[5]
L Lavie.
Obstructive sleep apnoea syndrome: an oxidative stress disorder.
Sleep Med Rev, 7 (2003), pp. 35-51
[6]
RT Dean, I Wilcox.
Possible atherogenic effects of hypoxia during obstructive sleep apnea.
Sleep, 16 (1993), pp. 15-22
[7]
JA Hedner, I Wilcox, CE Sullivan.
Speculations on the interaction between vascular disease and obstructive sleep apnea. Sleep and breathing, Marcel Dekker, Inc., (1994),
[8]
B Halliwell, JMC Gutteridge.
Role of free radicals and catalytic metal ions in human diseases: an overview.
Methods Enzymol, 186 (1990), pp. 1-88
[9]
JI Elejalde.
Estrés oxidativo, enfermedades y tratamientos antioxidantes.
An Med Interna, 18 (2001), pp. 326-335
[10]
M Ballester.
Antioxidantes, radicales libres y salud. Un enfoque químico-orgánico-físico.
Med Clin (Barc), 107 (1996), pp. 509-515
[11]
KK Griendling, GA Fitzgerald.
Oxidative stress and cardiovascular injury. Part II: animal and human studies.
Circulation, 108 (2003), pp. 2034-2040
[12]
KK Griendling, GA Fitzgerald.
Oxidative stress and cardiovascular injury. Part I: basic mechanisms and in vivo monitoring of ROS.
Circulation, 108 (2003), pp. 1912-1916
[13]
KM Channon, TJ Guzik.
Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors.
J Physiol Pharmacol, 53 (2002), pp. 515-524
[14]
JG Umans, R Levi.
Nitric oxide in the regulation of blood flow and arterial pressure.
Annu Rev Physiol, 57 (1995), pp. 771-790
[15]
K Irani.
Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling.
Circ Res, 87 (2000), pp. 179-183
[16]
JW Heinecke.
Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis.
Am J Cardiol, 91 (2003), pp. 12A-16A
[17]
BE Fenster, PS Tsao, SG Rockson.
Endothelial dysfunction: clinical strategies for treating oxidant stress.
Am Heart J, 146 (2003), pp. 218-226
[18]
D Harrison, KK Griendling, U Landmesser, B Hornig, H Drexler.
Role of oxidative stress in atherosclerosis.
Am J Cardiol, 91 (2003), pp. 7A-11A
[19]
C Kunsch, RM Medford.
Oxidative stress as a regulator of gene expression in the vasculature.
Circ Res, 85 (1999), pp. 753-766
[20]
TJ Guzik, NEJ West, E Black, D McDonald, C Ratnatunga, R Pillai, et al.
Functional effect of the C242T polymorphism in the NADPH oxidase p22phox subunit on vascular superoxide production in atherosclerosis.
Circulation, 102 (2000), pp. 1744-1747
[21]
JA Lawson, J Rokach, GA Fitzgerald.
Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo.
J Biol Chem, 274 (1999), pp. 24441-24444
[22]
S Lorch, R Lightfoot, H Ohshima, L Virag, Q Chen, C Hertkom, et al.
Detection of peroxynitrite-induced protein and DNA modifications.
Methods Mol Biol, 196 (2002), pp. 247-275
[23]
LJ Roberts, JD Morrow.
Products of the isoprostane pathway: unique bioactive compounds and markers of lipid peroxidation.
Cell Mol Life Sci, 59 (2002), pp. 808-820
[24]
S Tsimikas, JL Witzum.
Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk.
Circulation, 103 (2001), pp. 1930-1932
[25]
G Davi, P Alessandrini, A Mezzetti, G Minotti, T Bucciarelli, F Costantini, et al.
In vivo formation of 8-epiprostaglandin F2 alpha is increased in hypercholesterolemia.
Arterioscler Thromb Vasc Biol, 17 (1997), pp. 3230-3235
[26]
MP Reilly, D Pratico, N Delanty, G DiMinno, E Tremoli, D Rader, et al.
Increased formation of distinct F2 isoprostanes in hypercholesterolemia.
Circulation, 98 (1998), pp. 2822-2828
[27]
JD Morrow, B Frei, AW Longmire, JM Gaziano, SM Lynch, Y Shyr, et al.
Increase in circulating products of lipid peroxidation (F2-isoporstanes) in smokers: smoking as a cause of oxidative damage.
N Engl J Med, 332 (1995), pp. 1198-1203
[28]
M Reilly, N Delanty, JA Lawson, GA Fitzgerald.
Modulation of oxidant stress in vivo in cigarette smokers.
Circulation, 94 (1996), pp. 19-25
[29]
G Davi, MT Guagnano, G Ciabattoni, S Basili, A Falco, M Marinopiccoli, et al.
Platelet activation in obese women: role of inflammation and oxidant stress.
JAMA, 288 (2002), pp. 2008-2014
[30]
D Practico, RK Tangirala, DJ Rader.
Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice.
Nat Med, 4 (1998), pp. 1189-1192
[31]
GL Nunes, K Robinson, A Kalynych, SB King, DS Sgoutas, BC Berk.
Vitamins C and E inhibit O2- production in the pig coronary artery.
Circulation, 96 (1997), pp. 3593-3601
[32]
A Freyschuss, A StikoRahm, J Swedenborg, P Henrikson, I Bjorkhem, L Berglurd, et al.
Antioxidant treatment inhibits the development of intimal thickening after balloon injury of the aorta in hypercholesterolemic rabbits.
J Clin Invest, 91 (1993), pp. 1282-1288
[33]
C Weber, W Erl, K Weber, PC Weber.
Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers.
Circulation, 93 (1996), pp. 1488-1492
[34]
HH Ting, FK Timimi, KS Boles, SJ Creager, P Ganz, MA Greager.
Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus.
J Clin Invest, 97 (1996), pp. 22-28
[35]
NG Stephens, A Parsons, PM Schofield, F Kelly, K Cheeseman, MJ Mitchinson.
Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS).
Lancet, 347 (1996), pp. 781-786
[36]
S Yusuf, G Dagenais, J Pogue, J Bosch, P Sleight.
Vitamin E supplementation and cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study investigators.
N Engl J Med, 342 (2000), pp. 154-160
[37]
NR Prabhakar.
Sleep apneas. An oxidative stress?.
Am J Respir Crit Care Med, 165 (2002), pp. 859-860
[38]
R Schulz, S Mahmoudi, K Hattar, U Sibelius, H Olschewski, K Mayer, et al.
Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy.
Am J Respir Crit Care Med, 162 (2000), pp. 566-570
[39]
L Dyugovskaya, P Lavie, L Lavie.
Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients.
Am J Respir Crit Care Med, 165 (2002), pp. 934-939
[41]
SO Wali, AS Bahammam, H Massaeli, GN Pierce, N IIiskovic, PK Singal, et al.
Susceptibility of LDL to oxidative stress in obstructive sleep apnea.
Sleep, 21 (1998), pp. 290-296
[42]
A Barceló, C Miralles, F Barbe, M Vila, S Pons, AGN Agustí.
Abnormal lipid peroxidation in patients with sleep apnea.
Eur Respir J, 16 (2000), pp. 644-647
[43]
L Lavie, A Vishnevsky, P Lavie.
Evidence for lipid peroxidation in obstructive sleep apnea.
Sleep, 27 (2004), pp. 123-128
[44]
S Saarelainen, T Lehtimäki, O Jaakkola, T Poussa, M Nikkilä, T Solakivi, et al.
Autoantibodies against oxidised low-density lipoprotein in patients with obstructive sleep apnoea.
Clin Chem Lab Med, 37 (1999), pp. 517-520
[45]
AA Mangoni, SH Jackson.
Homocysteine and cardiovascular disease: current evidence and future prospects.
Am J Med, 112 (2002), pp. 556-565
[46]
R Clarke, D Stansbie.
Assessment of homocysteine as a cardiovascular risk factor in clinical practice.
Ann Clin Biochem, 38 (2001), pp. 624-632
[47]
L Lavie, A Perelman, P Lavie.
Plasma homocysteine levels in obstructive sleep apnea. association with cardiovascular morbidity.
Chest, 120 (2001), pp. 900-908
[48]
E Stroes, J Kastelein, F Cosentino, W Erkelens, R Wever, H Koomans, et al.
Tetrahydrobiopterin restores endothelial function in hypercholesterolemia.
J Clin Invest, 99 (1997), pp. 41-46
[49]
T Heitzer, C Brockhoff, B Mayer, A Wamholtz, H Mollnan, S Henne, et al.
Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase.
Circ Res, 86 (2000), pp. E36-E41
[50]
MSM Ip, B Lam, L-Y Chan, L Zheng, KWT Tsang, PCW Fung, et al.
Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure.
Am J Respir Crit Care Med, 162 (2000), pp. 2166-2171
[51]
R Schulz, D Schmidt, A Blum, X Lopes-Ribeiro, C Lücke, K Mayer, et al.
Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy.
Thorax, 55 (2000), pp. 1046-1051
[52]
J Carlson, J Hedner, A Patterson.
Increased plasma concentration of ADMA, a naturally occurring nitric oxide synthesis inhibitor in OSA patients.
Am J Respir Crit Care Med, 155 (1997), pp. A869
[53]
H Sahebjami.
Changes in urinary uric acid excretion in obstructive sleep apnea before and after therapy with nasal continuous positive airway pressure.
Chest, 113 (1998), pp. 1604
[54]
LJ Findley, M Boykin, T Fallon, L Belardinelli.
Plasma adenosine and hypoxaemia in patients with sleep apnea.
J Appl Physiol, 64 (1988), pp. 556-561
[55]
JD Hasday, CM Grum.
Nocturnal increase of urinary uric acid: creatinine ratio. A biochemical correlate of sleep-associated hypoxaemia.
Am Rev Respir Dis, 135 (1987), pp. 534-538
[56]
A Braghiroli, C Sacco, M Erbetta, V Ruga, CF Donner.
Overnight urinary uric acid: creatinine ratio for detection of sleep hypoxaemia. Validation study in chronic obstructive pulmonary disease and obstructive sleep apnea before and after treatment with nasal continuous positive airway pressure.
Am Rev Respir Dis, 148 (1993), pp. 173-178
[57]
GL Semenza.
Oxygen regulated transcription factors and their role in pulmonary disease.
Respir Res, 1 (2000), pp. 159-162
[58]
L Piacentini, JS Karliner.
Altered gene expression during hypoxia and reoxygenation of the heart.
Pharmacol Ther, 83 (1999), pp. 21-37
[59]
J Neubauer.
Physiological and genomic consequences of intermittent hypoxia. Invited review: physiological and pathophysiological responses to intermittent hypoxia.
J Appl Physiol, 90 (2001), pp. 1593-1599
[60]
L Lavie, H Kraiczi, A Hefetz, H Ghandour, A Perelman, J Hedner, et al.
Plasma vascular endothelial growth factor in sleep apnea syndrome. Effects of nasal continuous positive air pressure treatment.
Am J Respir Crit Care Med, 165 (2002), pp. 1624-1628
[61]
D Gozal, AJ Lipton, KL Jones.
Circulating vascular endothelial growth factor levels in patients with obstructive sleep apnea.
Sleep, 25 (2002), pp. 59-65
[62]
S Imagawa, Y Yamaguchi, M Higuchi, T Neichi, Y Hasegawa, HY Mukai, et al.
Levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea-hypopnea syndrome.
Blood, 98 (2001), pp. 1255-1257
[63]
R Schulz, C Hummel, S Heinemann, W Seeger, F Grimminger.
Serum levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia.
Am J Respir Crit Care Med, 165 (2002), pp. 67-70
[64]
S Saarelainen, J Hasan.
Circulating endothelin-1 and obstructive sleep apnoea.
Eur Respir J, 16 (2000), pp. 794-795
[65]
AN Vgontzas, DA Papanicolaou, EO Bixler, K Hopper, A Lotsikas, HM Lin.
Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance and hypercytokinemia.
J Clin Endocrinol Metab, 85 (2000), pp. 1151-1158
[66]
P Entzian, k Linnemann, M Schlaak, P Zabel.
Obstructive sleep apnea syndrome and circadian rhythms of hormones and cytokines.
Am J Respir Crit Care Med, 153 (1996), pp. 1080-1086
[67]
K Chin, T Nakamura, K Shimizu, M Mishima, T Nakamura, M Miyasaka, et al.
Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome.
Am J Med, 109 (2000), pp. 562-567
[68]
E Ohga, T Nagase, T Tomita, S Teramoto, T Matsuse, H Katayama, et al.
Increased levels of circulating ICAM-I, VCAM-I, and L-selectin in obstructive sleep apnea syndrome.
J Appl Physiol, 87 (1999), pp. 10-14
[69]
AA el-Solh, MJ Mador, P Sikka, RS Dhillon, D Amsterdam, BJ Grant.
Adhesion molecules in patients with coronary artery disease and moderate-to severe obstructive sleep apnea.
Chest, 121 (2002), pp. 1541-1547
[70]
T Yokoe, K Minoguchi, H Matsuo, N Oda, H Minoguchi, G Yoshino, et al.
Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure.
Circulation, 107 (2003), pp. 1129-1134
[71]
ASM Shamsuzzaman, M Winnicki, P Lanfranchi, R Wolk, T Kara, V Accurso, et al.
Elevated C-reactive protein in patients with obstructive sleep apnea.
Circulation, 105 (2002), pp. 2462-2464
[72]
A Barceló, F Barbé, E Llompart, LR Mayoralas, A Ladaria, M Bosch, et al.
Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea.
Am J Med, 117 (2004), pp. 118-121
[73]
A Barceló, F Barbé.
Las citocinas en la patogenia del síndrome de apneas/hipopneas del sueño. Trastornos respiratorios del sueño. Monografía de la Sociedad Madrileña de Neumología y Cirugía Torácica, pp. 149-216
The following agencies or foundations supported this study: ABEMAR, SEPAR, Fondo de Investigaciones Sanitarias (01/0786, 02/0334), and Red Respira (RTIC C03/11).
Copyright © 2005. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
